NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all persons or entities that: (a) sold or otherwise disposed of the publicly-trade ...

NEW YORK, May 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cerevel-therapeutics-holdings-inc-loss-submission-form/?id=148824&from=4 ...

Here are three dividend-paying stocks that warrant closer examination.Dividend stocks can be a smart way to generate steady income, especially in uncertain markets. However, not all dividend payers are created equal. A recent study from Ned Davis Research and Hartford Funds found that companies able to grow their dividends over time have historically delivered higher total returns with less volatility than those that merely held steady or slashed their payouts.With that in mind, let's take a closer look at ...

报告行业投资评级 未提及相关内容 报告的核心观点 报告聚焦创新药领域，围绕NSCLC中MET靶点展开研究，介绍MET失调机制、获批疗法及艾伯维MET ADC药物进展，还涵盖本周创新药企表现、国产新药申报、企业公告、交易事件及全球创新药获批情况等内容，为投资者提供行业动态和潜在投资机会参考[9][19][39] 根据相关目录分别进行总结 第一部分：本周创新药重点关注 国内创新药回顾 - 本周创新药企涨跌幅：涨幅前5为兆科眼科（+30.91%）、君圣泰（+19.78%）、德琪医药（+18.34%）、思路迪（+14.57%）、嘉和生物（+14.48%）；跌幅前5为歌礼制药（-17.10%）、传奇生物（-12.59%）、康宁杰瑞制药（-8.72%）、云顶新耀（-7.77%）、康乃德（-7.26%）[39] - Biotech公司最新市值：恒瑞3435亿元、百济神州1285亿元等[43] - 国产新药IND数量为25个，NDA数量为4个，涉及嘉因生物、君赛生物等多家企业[44] - 本周创新药企公告：诺诚健华一季度营收增长，科济药业批准股份购回计划，恒瑞医药公告H股上市，复宏汉霖获纳入指数及启动临床，荣昌生物临床研究达终点及新药申请获受理，贝达药业递交药品上市申请，泽璟制药新药上市申请获受理，和誉将汇报临床试验数据[46] - 本周创新药交易事件：涉及望石智慧、石药集团等多家企业，交易类型包括合作、许可、资产收购等，总交易金额有10.65亿美元、13.00亿美元等[48] 全球新药速递 - NSCLC中的MET信号通路失调：肺癌常见，NSCLC约占85%，MET失调会促进肿瘤侵袭等，MET蛋白过表达是常见失调形式，不同类型MET改变发生率和临床意义有差异[9][14] - NSCLC适应症中靶向MET的获批疗法：已有多种药物获批，多为小分子抑制剂，对MET ex14跳变患者有效，对MET过表达肿瘤无效，艾伯维telisotuzumab vedotin成全球首款获批MET ADC药物[19] - 艾伯维：全球首款MET ADC美国获批单药治疗EGFR WT NSCLC：5月14日FDA加速批准Teliso - V治疗MET蛋白高过表达患者，基于II期临床试验LUMINOSITY数据，公司还开展全球III期临床[24] - 艾伯维：MET ADC联用奥希替尼治疗EGFR突变型NSCLC：I/Ib期研究表明组合用药有效且可耐受，常见TEAE为周围感觉神经病变等，5例TEAE导致死亡但与药物无关[29] - MET ADC药物竞争格局：艾伯维领先，除Teliso - V获批，ABBV - 400结直肠癌适应症进展至临床III期，还有荣昌生物RC108、恒瑞医药SHR - 1826等处于临床II期[30][31] - 艾伯维：新一代MET ADC ABBV - 400在多种实体瘤中有抗肿瘤活性：I期研究显示其在CRC、GEA、EGFR野生型nsq - NSCLC等实体瘤中有可耐受安全性和抗肿瘤活性[35] - 荣昌生物RC108：针对MET阳性晚期实体瘤I期临床研究推进，与信达生物合作开展联合用药研究，联合EGFR TKI伏美替尼临床研究数据将发布[36] - 恒瑞医药SHR - 1826：开展多中心开放Ib/II期临床研究，单药治疗晚期实体瘤I期临床也在进行中[36] 第三部分：本周创新药重点关注 国内创新药回顾 未提及相关内容 全球创新药速递 - 默沙东：HIF - 2α抑制剂获FDA批准治疗罕见肿瘤PPGL：5月14日FDA批准belzutifan治疗PPGL，基于II期临床试验LITESPARK - 015数据，这是其在美国获批的第三项适应症[52] - 默沙东：K药联合化疗±贝伐治疗铂类耐药卵巢癌III期试验成功：5月15日宣布III期临床KEYNOTE - B96试验达到PFS主要终点和PD - L1阳性患者OS次要终点，试验继续进行，安全性与先前报告一致[53]

Make money without even trying: That's what passive income is all about. But good investment alternatives are required to make this "easy" money.Three Motley Fool contributors believe they have found some great dividend stocks that fit the bill. Here's why they think Abbott Laboratories (ABT 1.08%), AbbVie (ABBV 1.30%), and Johnson & Johnson (JNJ 1.19%) are magnificent stocks that are passive income machines. A dividend stock you can buy and (almost) forget aboutDavid Jagielski (Abbott Laboratories): When p ...

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all persons or entities that: (a) sold or otherwise disposed of the publicly-trade ...

CANADA - 2025/04/03: In this photo illustration, the AbbVie logo is seen displayed on a smartphone ... More screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images AbbVie (NYSE:ABBV) stock has garnered recent attention following the FDA approval of Emrelis for adults with previously treated lung cancer who exhibit an overabundance of the c-Met protein. This protein is known to promote tumor growth and resistance to certain therapies. Thi ...

NEW YORK, May 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all persons or entities that: (a) sold or otherwise disposed of the publicly-traded com ...

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/cerevel-therapeutics-holdings-inc-loss-submission-form/?id=148463 ...

AbbVie (ABBV) announced that the FDA has granted accelerated approval to its antibody-drug conjugate (ADC), telisotuzumab vedotin (or Teliso-V), for treating certain patients with non-small cell lung cancer (NSCLC). The drug will be marketed under the brand name Emrelis.Under this approval, Emrelis is approved to treat adult patients with locally advanced or metastatic, non-squamous NSCLC with high c-Met protein overexpression (OE) who have received a prior systemic therapy. This makes it the first FDA-appr ...